CUMULATIVE
SUPPLEMENT 6
JUN'99



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGMENT AND SERVICES

1999

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

Cumulative Supplement 6

JUNE 1999

CONTENTS

		PAGE
1.0	INTRODUCTION	iii
1.1	How to Use the Cumulative Supplement	iii
1.2	Applicant Name Changes	iv
1.3	Diclofenac Sodium Ophthalmic Solution	v
1.4	Availability of the Edition	vi
1.5	Report of Counts for the Prescription Drug Product List	vii
2.0	DRUG PRODUCT LISTS	
2.1	Prescription Drug Product List	1
2.2	OTC Drug Product List	31
2.3	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	34
2.4	Orphan Product Designations and Approvals List	35
2.5	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	45
	PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
	A. Patent and Exclusivity Terms	46
	B. Patent and Exclusivity Lists	48

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

CUMULATIVE SUPPLEMENT 6
JUNE 1999

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 19th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 19th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 20th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)

NO APPLICANT NAME CHANGES – JUNE 1999

1.3 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.4 AVAILABILITY OF THE EDITION

The 19th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $78.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 19th annual edition of the 1998 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder/orange/19bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at
http://www.fda.gov/cder/orange/supplement/patents.pdf.

The current listing of the Orphan Product Designations and Approvals is available at
http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1998) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1998	MAR 1999	JUN 1999	SEP 1999
DRUG PRODUCTS LISTED	9923	9975	10009	
SINGLE SOURCE	2504 (25.2%)	2520 (25.3%)	2523 (25.2%)	
MULTISOURCE	7308 (73.6%)	7344 (73.6%)	7375 (73.7%)	
THERAPEUTICALLY EQUIVALENT	6934 (69.9%)	6969 (69.9%)	7012 (70.1%)	
NOT THERAPEUTICALLY EQUIVALENT	374 (3.8%)	375 (3.8%)	363 (3.6%)	
EXCEPTIONS[1]	111 (1.1%)	111 (1.1%)	111 (1.1%)	
NEW MOLECULAR ENTITIES APPROVED	10	3	5	
NUMBER OF APPLICANTS	563	570	568	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

	ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODONE BITARTRATE				
	+ MIKART	712.8MG;60MG;32MG	N40316 001 APR 28, 1999		

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

	ALLAY				
AA	NORTON HN	500MG;5MG	N89907 001 JAN 13, 1989	> ADD >	
				> ADD >	
AA	ZENITH GOLDLINE	500MG;5MG	N89907 001 JAN 13, 1989	> ADD >	
				> ADD >	
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			> DLT >	
AA	MALLINCKRODT	500MG;5MG	N88956 001 JUL 19, 1985	> DLT >	
				> DLT >	
	ZYDONE			> DLT >	
AA	MALLINCKRODT	500MG;5MG	N88956 001 JUL 19, 1985		

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

	OXYCODONE AND ACETAMINOPHEN				
AA	DURAMED	500MG;5MG	N40289 001 MAR 16, 1999		

TABLET; ORAL

	OXYCODONE AND ACETAMINOPHEN				
AA	AMIDE PHARM	325MG;5MG	N40203 001 MAR 15, 1999		
	PERCOCET				
AA	ENDO PHARMS	325MG;5MG	N40330 002 JUN 25, 1999	> ADD >	
				> ADD >	
		325MG;2.5MG	N40330 001 JUN 25, 1999	> ADD >	
				> ADD >	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	PROPACET 100				
AB	TEVA	650MG;100MG	N70107 001 JUN 12, 1985		

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	PROPACET 100				
	@ TEVA	650MG;100MG	N70107 001 JUN 12, 1985		

ACITRETIN

CAPSULE; ORAL

	SORIATANE				
	HLR	10MG	N19821 001 OCT 28, 1996		
		25MG	N19821 002 OCT 28, 1996		
	+				
	ROCHE	10MG	N19821 001 OCT 28, 1996		
	+	25MG	N19821 002 OCT 28, 1996		

ACYCLOVIR

CAPSULE; ORAL

	ACYCLOVIR				
AB	STASON	200MG	N75090 001 JAN 26, 1999		

TABLET; ORAL

	ACYCLOVIR				
AB	CARLSBAD	400MG	N75382 001 APR 30, 1999		
AB		800MG	N75382 002 APR 30, 1999		

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

	ACYCLOVIR SODIUM				
AP	+ AM PHARM PARTNERS	EQ 50MG BASE/ML	N74930 001 MAY 13, 1998		
	+	EQ 50MG BASE/ML	N74930 001 MAY 13, 1998		
AP	MERIDIAN MEDCL TECHN	EQ 50MG BASE/ML	N75065 001 FEB 25, 1999		

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL
AB MEDEVA 0.09MG/INH N72273 001 AUG 14, 1996
AB MEDEVA PHARMS MA 0.09MG/INH N72273 001 AUG 14, 1996

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE
AN HI TECH PHARMA EQ 0.083% BASE N75063 001 FEB 09, 1999

SYRUP; ORAL
ALBUTEROL SULFATE
AA UDL EQ 2MG BASE/5ML N75262 001 MAR 30, 1999

ALITRETINOIN

GEL; TOPICAL
PANRETIN
+ LIGAND EQ 0.1% BASE N20886 001 FEB 02, 1999

ALLOPURINOL

TABLET; ORAL
ZYLOPRIM
AB FARO PHARMS 100MG N16084 001
AB + 300MG N16084 002
AB GLAXO WELLCOME 100MG N16084 001
AB + 300MG N16084 002

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION
CERNEVIT-12
+ BAXTER HLTHCARE 11.2 IU/VIAL;125MG/VIAL;60 UGM/VIAL; 200 IU/VIAL;5.5MG/VIAL;414 UGM/VIAL; 46MG/VIAL;17.25MG/VIAL;4.53MG/VIAL; 4.14MG/VIAL;3.51MG/VIAL; 3,500 IU/VIAL N20924 001 APR 06, 1999

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL
AP GENSIA SICOR PHARMS 0.5MG/ML N75196 001 APR 30, 1999

AMCINONIDE

CREAM; TOPICAL
CYCLOCORT
@ FUJISAWA HLTHCARE 0.025% N18116 001
+ 0.1% N18116 002
+ LEDERLE 0.025% N18116 001
+ 0.1% N18116 002

LOTION; TOPICAL
CYCLOCORT
+ FUJISAWA HLTHCARE 0.1% N19729 001 JUN 13, 1988
+ LEDERLE 0.1% N19729 001 JUN 13, 1988

OINTMENT; TOPICAL
CYCLOCORT
+ FUJISAWA HLTHCARE 0.1% N18498 001
+ WYETH AYERST 0.1% N18498 001

AMINO ACIDS

INJECTABLE; INJECTION
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
> ADD > FRESENIUS KABI 5.2% N18901 001
> ADD > APR 06, 1984

AMINO ACIDS

INJECTABLE; INJECTION

	AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE				
> DLT >	PHARMACIA AND UPJOHN	5.2%		N18901 001	APR 06, 1984
> DLT >					
	NEOPHAM 6.4%				
> ADD >	@ FRESENIUS KABI	6.4%		N18792 001	JAN 17, 1984
> ADD >					
> DLT >	@ PHARMACIA AND UPJOHN	6.4%		N18792 001	JAN 17, 1984
> DLT >					
	NOVAMINE 11.4%				
> ADD >	FRESENIUS KABI	11.4%		N17957 003	AUG 09, 1982
> ADD >					
> DLT >	PHARMACIA AND UPJOHN	11.4%		N17957 003	AUG 09, 1982
> DLT >					
	NOVAMINE 15%				
> ADD >	FRESENIUS KABI	15%		N17957 004	NOV 28, 1986
> ADD >					
> DLT >	PHARMACIA AND UPJOHN	15%		N17957 004	NOV 28, 1986
> DLT >					
	NOVAMINE 8.5%				
> ADD >	@ FRESENIUS KABI	8.5%		N17957 002	AUG 09, 1982
> ADD >					
> DLT >	@ PHARMACIA AND UPJOHN	8.5%		N17957 002	AUG 09, 1982
> DLT >					

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

	VEINAMINE 8%			
> ADD >	@ FRESENIUS KABI	8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML	N17957 001	
> ADD >				
> DLT >	@ PHARMACIA AND UPJOHN	8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML	N17957 001	
> DLT >				

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

	AMIODARONE HCL			
AB	ALPHAPHARM	200MG	**N75188 001**	FEB 24, 1999
AB	NOVOPHARM	200MG	**N74895 001**	APR 16, 1999

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	ENDEP			
AB	ROCHE	10MG	**N83639 001**	
AB		25MG	**N83639 002**	
AB		50MG	**N83639 003**	
AB		75MG	**N83639 004**	
AB		100MG	**N83639 005**	
	@	10MG	N83639 001	
	@	25MG	N83639 002	
	@	50MG	N83639 003	
	@	75MG	N83639 004	
	@	100MG	N83639 005	

AMOXICILLIN

CAPSULE; ORAL

	AMOXICILLIN			
AB	RANBAXY	250MG	**N65016 001**	APR 08, 1999
AB		500MG	**N65016 002**	APR 08, 1999

POWDER FOR RECONSTITUTION; ORAL

	AMOXIL			
	SMITHKLINE BEECHAM	200MG/5ML	N50760 001	APR 15, 1999
+		400MG/5ML	N50760 002	APR 15, 1999

TABLET, CHEWABLE; ORAL

	AMOXIL			
	SMITHKLINE BEECHAM	200MG	N50761 001	APR 15, 1999
+		400MG	N50761 002	APR 15, 1999

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

	AMPHOTEC			
> ADD >	+ ALZA	50MG/VIAL	N50729 001	NOV 22, 1996
> ADD >				
> ADD >	+	100MG/VIAL	N50729 002	NOV 22, 1996
> ADD >				

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION
AMPHOTEC

>_DLT_>	+	SEQUUS	50MG/VIAL	N50729 001 NOV 22, 1996
>_DLT_>	+		100MG/VIAL	N50729 002 NOV 22, 1996
>_DLT_>				
>_DLT_>				

AMPRENAVIR

CAPSULE; ORAL
AGENERASE

	GLAXO WELLCOME	50MG	N21007 001 APR 15, 1999
	+	150MG	N21007 002 APR 15, 1999

SOLUTION; ORAL
AGENERASE

	+ GLAXO WELLCOME	15MG/ML	N21039 001 APR 15, 1999

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
KABIVITE PED F + W KIT

>_ADD_>	+	FRESENIUS KABI	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A	N20176 001 DEC 29, 1993
>_ADD_>				
>_ADD_>				
>_ADD_>				
>_ADD_>				
>_ADD_>				
>_ADD_>				
>_ADD_>				
>_DLT_>	+	PHARMACIA AND UPJOHN	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A	N20176 001 DEC 29, 1993
>_DLT_>				
>_DLT_>				
>_DLT_>				
>_DLT_>				
>_DLT_>				
>_DLT_>				
>_DLT_>				

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB	ENDO PHARMS	325MG;50MG;40MG;30MG	N75351 001 MAR 05, 1999

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB	STEVENS J	385MG;30MG;25MG	N74988 001 APR 30, 1999
AB		770MG;60MG;50MG	N74988 002 APR 30, 1999

ASTEMIZOLE

TABLET; ORAL
HISMANAL

>_DLT_>	+	JANSSEN	10MG	N19402 001 DEC 29, 1988
>_DLT_>				
>_ADD_>	@		10MG	N19402 001 DEC 29, 1988
>_ADD_>				

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	APOTHECON	50MG	N73317 001 MAR 20, 1992
AB		100MG	N73318 001 MAR 20, 1992
	@	50MG	N73317 001 MAR 20, 1992
	@	100MG	N73318 001 MAR 20, 1992

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL W/ ATROPINE SULFATE

AA	ZENITH GOLDLINE	0.025MG;2.5MG	N86727 001
	@	0.025MG;2.5MG	N86727 001

AZATHIOPRINE

TABLET; ORAL
AZATHIOPRINE

>ADD>	AB		APPLIED ANAL	50MG	N75252 001	
>ADD>					JUN 07, 1999	

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

>DLT>	AT	+	ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;		
>DLT>				10,000 UNITS/GM	N60731 002	
>ADD>		@		400 UNITS/GM;1%;EQ 3.5MG BASE/GM;		
>ADD>				10,000 UNITS/GM	N60731 002	
>DLT>	AT		PHARMADERM	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;		
>DLT>				10,000 UNITS/GM	N62166 002	
>ADD>		+		400 UNITS/GM;1%;EQ 3.5MG BASE/GM;		
>ADD>				10,000 UNITS/GM	N62166 002	

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL
CORZIDE

		APOTHECON	5MG;40MG	N18647 001	
				MAY 25, 1983	
	+		5MG;80MG	N18647 002	
				MAY 25, 1983	
		BRISTOL MYERS SQUIBB	5MG;40MG	N18647 001	
				MAY 25, 1983	
	+		5MG;80MG	N18647 002	
				MAY 25, 1983	

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
PRE-PEN

>DLT>	+	BAYER	60 UMOLAR	N50114 001	
>ADD>	+	HOLLISTER STIER LABS	60 UMOLAR	N50114 001	

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

>ADD>	AB		ALTANA	EQ 0.05% BASE	N75373 001	
>ADD>					JUN 22, 1999	

BETAMETHASONE VALERATE

AEROSOL; TOPICAL
LUXIQ

	+	CONNETICS	EQ 0.12% BASE	N20934 001	
				FEB 28, 1999	

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN

+	GLAXO WELLCOME	50MG	N20358 001	
			OCT 04, 1996	
+		100MG	N20358 002	
			OCT 04, 1996	
+		150MG	N20358 003	
			OCT 04, 1996	

WELLBUTRIN SR

+	GLAXO WELLCOME	50MG	N20358 001	
			OCT 04, 1996	
+		100MG	N20358 002	
			OCT 04, 1996	
+		150MG	N20358 003	
			OCT 04, 1996	

BUSULFAN

INJECTABLE; INJECTION
BUSULFEX

+	ORPHAN MEDCL	6MG/ML	N20954 001	
			FEB 04, 1999	

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT

+	SYNTEX	2%	N19215 001	
			NOV 25, 1985	

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

	FEMSTAT			
	@ SYNTEX	2%		N19215 001 NOV 25, 1985
	FEMSTAT ONE			
> ADD >	+ KV PHARM	2%		N19881 001 FEB 07, 1997
> DLT >	+ SYNTEX	2%		N19881 001 FEB 07, 1997

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

	ENDOSOL EXTRA			
AT	AKORN	0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML		N20079 001 NOV 27, 1991
AT	ALLERGAN	0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML		N20079 001 NOV 27, 1991

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER			
	B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML		N18271 001
	@	37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML		N18271 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

	ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER			
	B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML		N18269 002 JAN 17, 1983
	@	35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML		N18269 002 JAN 17, 1983

CAPECITABINE

TABLET; ORAL

	XELODA			
> ADD >	HLR	150MG		N20896 001 APR 30, 1998
> DLT >	ROCHE	150MG		N20896 001 APR 30, 1998

CAPTOPRIL

TABLET; ORAL

	CAPTOPRIL			
AB	BAKER NORTON	12.5MG		N74590 004 AUG 30, 1996
AB		25MG		N74590 002 AUG 30, 1996
AB		50MG		N74590 001 AUG 30, 1996
AB		100MG		N74590 003 AUG 30, 1996
AB	ZENITH GOLDLINE	12.5MG		N74590 004 AUG 30, 1996
AB		25MG		N74590 002 AUG 30, 1996
AB		50MG		N74590 001 AUG 30, 1996
AB		100MG		N74590 003 AUG 30, 1996

CARBENICILLIN DISODIUM

	INJECTABLE; INJECTION			
	GEOPEN			
	+ ROERIG	EQ 1GM BASE/VIAL	N50306 001	
	+	EQ 2GM BASE/VIAL	N50306 004	
	+	EQ 5GM BASE/VIAL	N50306 002	
	+	EQ 10GM BASE/VIAL	N50306 006	
	+	EQ 30GM BASE/VIAL	N50306 007	
	@	EQ 1GM BASE/VIAL	N50306 001	
	@	EQ 2GM BASE/VIAL	N50306 004	
	@	EQ 5GM BASE/VIAL	N50306 002	
	@	EQ 10GM BASE/VIAL	N50306 006	
	@	EQ 30GM BASE/VIAL	N50306 007	

CARTEOLOL HYDROCHLORIDE

	SOLUTION/DROPS; OPHTHALMIC			
	OCUPRESS			
	+ CIBA	1%	N19972 001	
			MAY 23, 1990	
	+ OTSUKA	1%	N19972 001	
			MAY 23, 1990	

CEFADROXIL/CEFADROXIL HEMIHYDRATE

	CAPSULE; ORAL			
	CEFADROXIL			
> ADD >	AB BARR	EQ 500MG BASE	N65015 001	
> ADD >			JUN 22, 1999	
	TABLET; ORAL			
	CEFADROXIL			
	AB RANBAXY	EQ 1GM BASE	N65018 001	
			APR 23, 1999	

CEFTAZIDIME (ARGININE FORMULATION)

	INJECTABLE; INJECTION			
	CEPTAZ			
AP	+ GLAXO WELLCOME	1GM/VIAL	N50646 002	
			SEP 27, 1990	
AP	+	2GM/VIAL	N50646 003	
			SEP 27, 1990	
AP	+	10GM/VIAL	N50646 004	
			SEP 27, 1990	

CEFTAZIDIME (ARGININE FORMULATION)

	INJECTABLE; INJECTION			
	CEPTAZ			
	+ GLAXO WELLCOME	1GM/VIAL	N50646 002	
			SEP 27, 1990	
	+	2GM/VIAL	N50646 003	
			SEP 27, 1990	
	+	10GM/VIAL	N50646 004	
			SEP 27, 1990	
	PENTACEF			
AP	SMITHKLINE BEECHAM	1GM/VIAL	N63322 001	
			NOV 07, 1995	
AP		1GM/VIAL	N64006 001	
			MAR 31, 1992	
AP		2GM/VIAL	N63322 002	
			NOV 07, 1995	
AP		2GM/VIAL	N64006 002	
			MAR 31, 1992	
AP		10GM/VIAL	N64008 002	
			MAR 31, 1992	
		6GM/VIAL	N64008 001	
			MAR 31, 1992	
	@	1GM/VIAL	N63322 001	
			NOV 07, 1995	
	@	1GM/VIAL	N64006 001	
			MAR 31, 1992	
	@	2GM/VIAL	N63322 002	
			NOV 07, 1995	
	@	2GM/VIAL	N64006 002	
			MAR 31, 1992	
	@	6GM/VIAL	N64008 001	
			MAR 31, 1992	
	@	10GM/VIAL	N64008 002	
			MAR 31, 1992	

CERIVASTATIN SODIUM

	TABLET; ORAL			
	BAYCOL			
	+ BAYER	0.3MG	N20740 004	
			JUN 26, 1997	
		0.3MG	N20740 004	
			JUN 26, 1997	
	+	0.4MG	N20740 005	
			MAY 24, 1999	

CHLOROTRIANISENE

CAPSULE; ORAL

> DLT >		CHLOROTRIANISENE			
> DLT >	AA	BANNER PHARMACAPS	12MG	N84652 001	
> ADD >		@	12MG	N84652 001	
		TACE			
> DLT >	AA	+ HOECHST MARION RSSL	12MG	N08102 004	
> ADD >		+	12MG	N08102 004	

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

		CHLORPROMAZINE HCL		
AA		PHARM ASSOC	100MG/ML	N40224 001 JAN 26, 1999

CHOLESTYRAMINE

POWDER; ORAL

		CHOLESTYRAMINE		
AB		BAKER NORTON	EQ 4GM RESIN/PACKET	N74771 001 JUL 09, 1997
AB			EQ 4GM RESIN/SCOOPFUL	N74771 002 JUL 09, 1997
AB		ZENITH GOLDLINE	EQ 4GM RESIN/PACKET	N74771 001 JUL 09, 1997
AB			EQ 4GM RESIN/SCOOPFUL	N74771 002 JUL 09, 1997
		CHOLESTYRAMINE LIGHT		
AB		COPLEY PHARM	EQ 4GM RESIN/SCOOPFUL	N74555 002 SEP 30, 1998

CILOSTAZOL

TABLET; ORAL

		PLETAL		
		OTSUKA	50MG	N20863 001 JAN 15, 1999
	+		100MG	N20863 002 JAN 15, 1999

CLOBETASOL PROPIONATE

CREAM; TOPICAL

> DLT >		CLOBETASOL PROPIONATE (EMOLLIENT)		
> DLT >	AB2	ALTANA	0.05%	N75430 001 MAY 26, 1999
> DLT >				
> ADD >		@	0.05%	N75430 001 MAY 26, 1999
> ADD >				

GEL; TOPICAL

		CLOBETASOL PROPIONATE		
AB		TARO	0.05%	N75279 001 MAY 28, 1999

SOLUTION; TOPICAL

		CLOBETASOL PROPIONATE		
AT		ALTANA	0.05%	N75391 001 FEB 08, 1999

CLOXACILLIN SODIUM

CAPSULE; ORAL

		CLOXAPEN		
AB		SMITHKLINE BEECHAM	EQ 250MG BASE	N62233 001
AB			EQ 500MG BASE	N62233 002
		@	EQ 250MG BASE	N62233 001
		@	EQ 500MG BASE	N62233 002

POWDER FOR RECONSTITUTION; ORAL

		CLOXACILLIN SODIUM		
AA		TEVA	EQ 125MG BASE/5ML	N62268 001
	+		EQ 125MG BASE/5ML	N62268 001
		TEGOPEN		
AA	+	APOTHECON	EQ 125MG BASE/5ML	N61453 001
		@	EQ 125MG BASE/5ML	N61453 001

CLOZAPINE

TABLET; ORAL

		CLOZAPINE		
AB		CREIGHTON	25MG	N74546 001 AUG 30, 1996
AB			100MG	N74546 002 AUG 30, 1996
AB		GENEVA PHARMS	25MG	N74546 001 AUG 30, 1996

CLOZAPINE

TABLET; ORAL
CLOZAPINE

AB	GENEVA PHARMS	100MG	N74546 002	AUG 30, 1996
AB	MYLAN	25MG	N75417 001	MAY 27, 1999
AB		100MG	N75417 002	MAY 27, 1999

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLISTIMETHATE

AP	PHARMA TEK	EQ 150MG BASE/VIAL	N64216 001	FEB 26, 1999

COLY-MYCIN M

AP	+ PARKEDALE	EQ 150MG BASE/VIAL	N50108 002	
	*	EQ 150MG BASE/VIAL	N50108 002	

CROMOLYN SODIUM

CAPSULE; ORAL
GASTROCROM

	* MEDEVA	100MG	N19188 001	DEC 22, 1989
	@	100MG	N19188 001	DEC 22, 1989

SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

>ADD<	AT	ALCON	4%	N75282 001	
>ADD<				JUN 16, 1999	

CROMOPTIC

AT	KING PHARMS	4%	N75088 001	APR 27, 1999

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION
CYSTEINE HCL

>ADD<	@ FRESENIUS KABI	7.25%	N19523 001	
>ADD<			OCT 22, 1986	
>DLT<	@ PHARMACIA AND UPJOHN	7.25%	N19523 001	
>DLT<			OCT 22, 1986	

CYTARABINE

INJECTABLE, LIPOSOMAL; INJECTION
DEPOCYT

+	DEPOTECH	10MG/ML	N21041 001	APR 01, 1999

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
CERUBIDINE

AP	+ BEDFORD	EQ 20MG BASE/VIAL	N64103 001	FEB 03, 1995
	*	EQ 20MG BASE/VIAL	N64103 001	FEB 03, 1995

DAUNORUBICIN HCL

AP	BIGMAR	EQ 20MG BASE/VIAL	N65000 001	MAY 25, 1999

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DDAVP

AB	+ RHONE POULENC RORER	0.01MG/SPRAY	N17922 003	AUG 07, 1996
	*	0.01MG/SPRAY	N17922 003	AUG 07, 1996

DESMOPRESSIN ACETATE

AB	BAUSCH AND LOMB	0.01MG/SPRAY	N74830 001	JAN 25, 1999

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
MAXITROL

AT	+ ALCON	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50065 002	
AT	+ FALCON PHARMS	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50065 002	

SUSPENSION/DROPS; OPHTHALMIC
MAXITROL

AT	+ ALCON	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50023 002	
AT	+ FALCON PHARMS	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50023 002	

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

AA	ENDO PHARMS	5MG	N40299 001	MAY 13, 1999

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

> DLT >		B BRAUN	5GM/100ML;110MG/100ML	N18030 005
> ADD >		@	5GM/100ML;110MG/100ML	N18030 005

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

> DLT >	AP	B BRAUN	5GM/100ML;200MG/100ML	N18030 004
> ADD >		@	5GM/100ML;200MG/100ML	N18030 004

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

> DLT >	AP	B BRAUN	5GM/100ML;330MG/100ML	N18030 003
> ADD >		@	5GM/100ML;330MG/100ML	N18030 003

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

> DLT >	AP	B BRAUN	5GM/100ML;450MG/100ML	N18030 002
> ADD >		@	5GM/100ML;450MG/100ML	N18030 002

DIAZEPAM

GEL; RECTAL
DIASTAT

	+	ATHENA	2.5MG/0.5ML	N20648 001 JUL 29, 1997
			5MG/ML	N20648 002 JUL 29, 1997
			10MG/2ML	N20648 003 JUL 29, 1997
			15MG/3ML	N20648 004 JUL 29, 1997
	+		20MG/4ML	N20648 005 JUL 29, 1997
> ADD >	+	ELAN PHARMS	2.5MG/0.5ML	N20648 001 JUL 29, 1997
			5MG/ML	N20648 002 JUL 29, 1997
			10MG/2ML	N20648 003 JUL 29, 1997
			15MG/3ML	N20648 004 JUL 29, 1997
	+		20MG/4ML	N20648 005 JUL 29, 1997

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM

AB		ALCON	0.1%	N20809 001 MAY 04, 1998
AB		FALCON PHARMS	0.1% †	N20809 001 MAY 04, 1998

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM

AB		MARTEC	50MG	N74986 001 FEB 26, 1999
AB			75MG	N74986 002 FEB 26, 1999
AB		NOVOPHARM	50MG	N74723 001 MAR 30, 1999

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL
DICYCLOMINE HCL

AB		LANNETT	20MG	N40230 001 FEB 26, 1999

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

> DLT > > DLT >	AB	TARO	0.05%	N75331 001 MAY 14, 1999

OINTMENT; TOPICAL
DIFLORASONE DIACETATE

	AB	ALTANA	0.05%	N75374 001 APR 27, 1999
> ADD > > ADD >	AB	TARO	0.05%	N75331 001 MAY 14, 1999

PSORCON

	AB +	PHARMACIA AND UPJOHN	0.05%	N19260 001 AUG 28, 1985
	+		0.05%	N19260 001 AUG 28, 1985

† SEE SECTION 1.3 OF INTRODUCTION

† SEE SECTION 1.3 OF INTRODUCTION

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

AB3	+	CARDERM	120MG	N20062 001 AUG 10, 1992	
AB3	+		180MG	N20062 002 DEC 27, 1991	
AB3	+		240MG	N20062 003 DEC 27, 1991	
AB3	+		300MG	N20062 004 DEC 27, 1991	
BC	+		120MG	N20062 001 AUG 10, 1992	
BC	+		180MG	N20062 002 DEC 27, 1991	
BC	+		240MG	N20062 003 DEC 27, 1991	
BC	+		300MG	N20062 004 DEC 27, 1991	

CARTIA XT

AB3		ANDRX PHARMS	120MG	N74752 002 JUL 09, 1998	
AB3			180MG	N74752 001 JUL 09, 1998	
AB3			240MG	N74752 003 JUL 09, 1998	
AB3			300MG	N74752 004 JUL 09, 1998	> ADD >
	@		120MG	N74752 002 JUL 09, 1998	> ADD >
	@		180MG	N74752 001 JUL 09, 1998	> ADD >
	@		240MG	N74752 003 JUL 09, 1998	> ADD >
	@		300MG	N74752 004 JUL 09, 1998	

INJECTABLE; INJECTION

DILTIAZEM HCL

AP		MERIDIAN MEDCL TECHN	5MG/ML	N75106 001 APR 29, 1999	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DIPIVEFRIN HCL

AT		ALCON	0.1%	N73636 001 JUN 30, 1994	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DIPIVEFRIN HCL

AT		FALCON PHARMS	0.1%	N73636 001 JUN 30, 1994	

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB		PUREPAC PHARM	25MG	N89425 001 JUL 12, 1990	
	@		25MG	N89425 001 JUL 12, 1990	

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

	+	LILLY	250MG	N50678 001 JUN 19, 1995	
	+	SANOFI	250MG	N50678 001 JUN 19, 1995	

DOXERCALCIFEROL

CAPSULE; ORAL

HECTOROL

	+	BONE CARE	2.5 UGM	N20862 001 JUN 09, 1999	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

	+	ALZA	2MG/ML	N50718 001 NOV 17, 1995	
	+	SEQUUS	2MG/ML	N50718 001 NOV 17, 1995	

EPINEPHRINE

INJECTABLE; INJECTION

	SUS-PHRINE				
	+ FOREST LABS	5MG/ML	N07942 001		
	SUS-PHRINE SULFITE-FREE				
	FOREST LABS	1.5MG/AMP	N07942 003 FEB 05, 1999		
	+	5MG/ML	N07942 001		

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	CLIMARA				
BX	+ BERLEX LABS	0.025MG/24HR	N20375 004 MAR 05, 1999		
	ESTRADIOL				
AB	MENOREST	0.0375MG/24HR	N20538 001 JUL 31, 1996		
AB		0.05MG/24HR	N20538 003 JUL 31, 1996		
AB		0.075MG/24HR	N20538 002 JUL 31, 1996		
AB		0.1MG/24HR	N20538 004 JUL 31, 1996		
	VIVELLE-DOT				
AB	NOVARTIS	0.0375MG/24HR	N20538 001 JUL 31, 1996		
AB		0.05MG/24HR	N20538 003 JUL 31, 1996		
AB		0.075MG/24HR	N20538 002 JUL 31, 1996		
AB		0.1MG/24HR	N20538 004 JUL 31, 1996		

TABLET; ORAL

	ESTRADIOL				
AB	MYLAN	0.5MG	N40326 001 APR 21, 1999	> DLT >	> DLT >
AB		1MG	N40326 002 APR 21, 1999	> ADD >	> ADD >
AB		2MG	N40326 003 APR 21, 1999		

TABLET; VAGINAL

	VAGIFEM		
+	NOVO NORDISK	25 UGM	N20908 001 MAR 26, 1999

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

	CENESTIN		
	DURAMED	0.9MG	N20992 003 MAR 24, 1999
		0.625MG	N20992 002 MAR 24, 1999
+		0.9MG	N20992 003 MAR 24, 1999

ESTROPIPATE

CREAM; VAGINAL

	OGEN		
+	ABBOTT	1.5MG/GM	N84710 001
+	PHARMACIA AND UPJOHN	1.5MG/GM	N84710 001

TABLET; ORAL

	OGEN .625		
AB	ABBOTT	0.75MG	N83220 001
AB	PHARMACIA AND UPJOHN	0.75MG	N83220 001
	OGEN 1.25		
AB	ABBOTT	1.5MG	N83220 002
AB	PHARMACIA AND UPJOHN	1.5MG	N83220 002
	OGEN 2.5		
AB	+ ABBOTT	3MG	N83220 003
AB	+ PHARMACIA AND UPJOHN	3MG	N83220 003
	OGEN 5		
AB	ABBOTT	6MG	N83220 004
AB	PHARMACIA AND UPJOHN	6MG	N83220 004

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	LEVLITE		
	BERLEX LABS	0.02MG;0.1MG	N20860 001 JUL 13, 1998
+		0.02MG;0.1MG	N20860 001 JUL 13, 1998

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	BREVICON 21-DAY		
AB	SEARLE	0.035MG;0.5MG	N17566 001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	BREVICON 21-DAY			
AB	WATSON LABS	0.035MG;0.5MG	N17566 001	
	NORINYL 1+35 21-DAY			
AB	SEARLE	0.035MG;1MG	N17565 001	
AB	WATSON LABS	0.035MG;1MG	N17565 001	
	TRI-NORINYL 21-DAY			
	+ SEARLE	0.035MG,0.035MG;0.5MG,1MG	N18977 001 APR 13, 1984	
	+ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977 001 APR 13, 1984	

TABLET; ORAL-28

	BREVICON 28-DAY			
AB	SEARLE	0.035MG;0.5MG	N17743 001	
AB	WATSON LABS	0.035MG;0.5MG	N17743 001	
	NORINYL 1+35 28-DAY			
AB	SEARLE	0.035MG;1MG	N17565 002	
AB	WATSON LABS	0.035MG;1MG	N17565 002	
	TRI-NORINYL 28-DAY			
	SEARLE	0.035MG,0.035MG;0.5MG,1MG	N18977 002 APR 13, 1984	
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977 002 APR 13, 1984	

ETODOLAC

TABLET; ORAL

	ETODOLAC			
AB	NOVOPHARM	400MG	N74847 001 APR 23, 1999	
AB		500MG	N74847 002 APR 23, 1999	

ETOPOSIDE

INJECTABLE; INJECTION

	VEPESID			
AP	+ BRISTOL	20MG/ML	N18768 001 NOV 10, 1983	
AP	+ BRISTOL MYERS SQUIBB	20MG/ML	N18768 001 NOV 10, 1983	

FERRIC SODIUM GLUCONATE

INJECTABLE; INJECTION

	FERRLECIT			
	+ R AND D LABS	62.5MG/5ML	N20955 001 FEB 18, 1999	

FLUOCINONIDE

OINTMENT; TOPICAL

	FLUOCINONIDE			
> ADD > AB	TARO	0.05%	N75008 001 JUN 30, 1999	> ADD >

FLUOROURACIL

INJECTABLE; INJECTION

	FLUOROURACIL			
AP	BIGMAR	50MG/ML	N40291 001 MAR 24, 1999	

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL

	PROZAC			
	LILLY	EQ 10MG BASE	N20974 001 MAR 09, 1999	
	+	EQ 20MG BASE	N20974 002 MAR 09, 1999	
	+	EQ 10MG BASE	N20974 001 MAR 09, 1999	
	@	EQ 20MG BASE	N20974 002 MAR 09, 1999	

FUROSEMIDE

INJECTABLE; INJECTION

	FUROSEMIDE			
AP	ABBOTT	10MG/ML	N75241 001 MAY 28, 1999	

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION
PLAXEDIL

+	DAVIS AND GECK	20MG/ML	N07842 001	
+		100MG/ML	N07842 002	
@		20MG/ML	N07842 001	
@		100MG/ML	N07842 002	

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

AT	ALCON	EQ 0.3% BASE	N62196 001	
AT	FALCON PHARMS	EQ 0.3% BASE	N62196 001	

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

AB	MOVA	4.5MG	N74591 003 DEC 22, 1997	
		4.5MG	N74591 003 DEC 22, 1997	
AB	NOVOPHARM	1.5MG	N74686 001 APR 20, 1999	
AB		3MG	N74686 002 APR 20, 1999	
AB		4.5MG	N74686 003 APR 20, 1999	> ADD >
AB		6MG	N74686 004 APR 20, 1999	> ADD >

GLYCOPYRROLATE

TABLET; ORAL
ROBINUL

+	HORIZON PHARM	1MG	N12827 001
+	ROBINS AH	1MG	N12827 001

ROBINUL FORTE

+	HORIZON PHARM	2MG	N12827 002
+	ROBINS AH	2MG	N12827 002

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75393 001 MAY 11, 1999	
AO		EQ 100MG BASE/ML	N75393 002 MAY 11, 1999	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
AVALIDE

@	SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997	
		12.5MG;150MG	N20758 002 SEP 30, 1997	
+		12.5MG;300MG	N20758 003 AUG 31, 1998	

AVAPRO HCT

@	SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997	
+		12.5MG;150MG	N20758 002 SEP 30, 1997	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	DURAMED	25MG;37.5MG	N75052 001 JUN 18, 1999	

HYDROCORTISONE

ENEMA; RECTAL
CORTENEMA

AB	+ SOLVAY	100MG/60ML	N16199 001	
BR	+	100MG/60ML	N16199 001	

HYDROCORTISONE

AB	COPLEY PHARM	100MG/60ML	N74171 001 MAY 27, 1994	
BR		100MG/60ML	N74171 001 MAY 27, 1994	

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

	PAREDRINE			
+	AKORN	1%		N00004 004
+	PHARMICS	1%		N00004 004

HYDROXYUREA

CAPSULE; ORAL

	HYDROXYUREA			
AB	PAR PHARM	500MG		N75340 001 FEB 24, 1999

IBUPROFEN

SUSPENSION; ORAL

	MOTRIN			
AB	+ MCNEIL	100MG/5ML		N19842 001 SEP 19, 1989
AB	+ MCNEIL CONS	100MG/5ML		N19842 001 SEP 19, 1989

TABLET; ORAL

	IBUPROFEN			
AB	NORTON HN	400MG		N71145 001 SEP 23, 1986
AB		600MG		N71146 001 SEP 23, 1986
AB		800MG		N71769 001 MAY 08, 1987
AB	ZENITH GOLDLINE	400MG		N71145 001 SEP 23, 1986
AB		600MG		N71146 001 SEP 23, 1986
AB		800MG		N71769 001 MAY 08, 1987
	MOTRIN			
AB	MCNEIL	300MG		N17463 003
AB		400MG		N17463 002
AB		600MG		N17463 004
AB	+	800MG		N17463 005 MAY 22, 1985
		100MG		N20418 001 NOV 16, 1994
AB	MCNEIL CONS	300MG		N17463 003
AB		400MG		N17463 002

IBUPROFEN

TABLET; ORAL

	MOTRIN			
AB	MCNEIL CONS	600MG		N17463 004
AB	+	800MG		N17463 005 MAY 22, 1985
		100MG		N20418 001 NOV 16, 1994

TABLET, CHEWABLE; ORAL

	MOTRIN			
	MCNEIL	50MG		N20135 001 NOV 16, 1994
	+	100MG		N20135 002 NOV 16, 1994
	MCNEIL CONS	50MG		N20135 001 NOV 16, 1994
	+	100MG		N20135 002 NOV 16, 1994

INDOMETHACIN

CAPSULE; ORAL

	INDOMETHACIN			
AB	EON	75MG		N74464 001 MAY 28, 1998

CAPSULE, EXTENDED RELEASE; ORAL

	INDOMETHACIN			
AB	EON	75MG		N74464 001 MAY 28, 1998

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

	IPRATROPIUM BROMIDE			
AN	ALPHARMA	0.02%		N75111 001 APR 22, 1999

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

	ISOETHARINE HCL			
AN	INTL MEDICATION	0.08%		N86651 002
AN		0.1%		N86651 003

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

		ISOETHARINE HCL			
AN	+	INTL MEDICATION	0.1%	N86651 003	> ADD >
AN			0.167%	N86651 005	> ADD >
AN	+		0.167%	N86651 005	> ADD >
AN			0.25%	N86651 007	> ADD >
AN	+		0.25%	N86651 007	> ADD >
	+		0.08%	N86651 002	> ADD >
					> DLT >
		ISOETHARINE HCL S/F		N89817 001	> DLT >
AN	+	DEY	0.08%	NOV 22, 1988	> DLT >
AN	+		0.1%	N89818 001	> DLT >
AN	+		0.17%	NOV 22, 1988	> DLT >
AN	+		0.25%	N89819 001	> DLT >
				NOV 22, 1988	
				N89820 001	
				NOV 22, 1988	
	@		0.08%	N89817 001	
	@		0.1%	NOV 22, 1988	
	@		0.17%	N89818 001	
	@		0.25%	NOV 22, 1988	
				N89819 001	
				NOV 22, 1988	
				N89820 001	
				NOV 22, 1988	

ISOFLURANE

LIQUID; INHALATION

		FORANE			
AN	+	BAXTER PHARM PROD	99.9%	N17624 001	> ADD >
AN	+	OHMEDA	99.9%	N17624 001	> ADD >

ISOSORBIDE DINITRATE

TABLET; ORAL

		SORBITRATE			
AB		ZENECA	30MG	N88124 001	> ADD >
				AUG 21, 1990	> DLT >
	@		30MG	N88124 001	
				AUG 21, 1990	

ISOTRETINOIN

CAPSULE; ORAL

		ACCUTANE			
		HLR	10MG	N18662 002	
				MAY 07, 1982	
			20MG	N18662 004	
				MAR 28, 1983	
			40MG	N18662 003	
	+			MAY 07, 1982	
		ROCHE	10MG	N18662 002	
				MAY 07, 1982	
			20MG	N18662 004	
				MAR 28, 1983	
	*		40MG	N18662 003	
				MAY 07, 1982	

ITRACONAZOLE

INJECTABLE; INJECTION

	SPORANOX			
+	JANSSEN	10MG/ML	N20966 001	
			MAR 30, 1999	

KETOCONAZOLE

TABLET; ORAL

	KETOCONAZOLE			
AB	MUTUAL PHARMA	200MG	N75314 001	
			JUN 15, 1999	
AB	NOVOPHARM	200MG	N74971 001	
			JUN 15, 1999	
AB	SIDMAK LABS CA	200MG	N75362 001	
			JUN 15, 1999	
AB	TARO	200MG	N75319 001	
			JUN 15, 1999	
AB	TEVA	200MG	N75273 001	
			JUN 15, 1999	
	NIZORAL			
AB	+ JANSSEN	200MG	N18533 001	
	*	200MG	N18533 001	

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

	KETOPROFEN			
AB	ANDRX PHARMS	100MG	N75270 002	MAR 24, 1999
AB		150MG	N75270 003	MAR 24, 1999
AB		200MG	N75270 001	MAR 24, 1999
	ORUVAIL			
AB	WYETH AYERST	100MG	N19816 003	FEB 08, 1995
AB		150MG	N19816 002	FEB 08, 1995
		100MG	N19816 003	FEB 08, 1995
		150MG	N19816 002	FEB 08, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

	KETOROLAC TROMETHAMINE			
AP	ABBOTT	15MG/ML	N74993 001	JAN 27, 1999
AP		30MG/ML	N74993 002	JAN 27, 1999
AP	BEDFORD	15MG/ML	N75222 001	APR 26, 1999
AP		30MG/ML	N75222 002	APR 26, 1999
AP		30MG/ML	N75228 001	APR 26, 1999

TABLET; ORAL

	KETOROLAC TROMETHAMINE			
> ADD > AB	SIDMAK LABS CA	10MG	N75284 001	JUN 23, 1999
> ADD >				

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

	LABETALOL HCL			
AP	BEDFORD	5MG/ML	N75303 001	MAY 28, 1999

LABETALOL HYDROCHLORIDE

TABLET; ORAL

	TRANDATE			
AB	FARO PHARMS	100MG	N18716 001	MAY 24, 1985
AB		200MG	N18716 002	AUG 01, 1984
AB		300MG	N18716 003	AUG 01, 1984
@		400MG	N18716 004	AUG 01, 1984
AB	GLAXO WELLCOME	100MG	N18716 001	MAY 24, 1985
AB		200MG	N18716 002	AUG 01, 1984
AB		300MG	N18716 003	AUG 01, 1984
@		400MG	N18716 004	AUG 01, 1984

LAMIVUDINE

SOLUTION; ORAL

	EPIVIR-HBV			
+	GLAXO WELLCOME	5MG/ML	N21004 001	DEC 08, 1998
+		5MG/ML	N20596 002	DEC 08, 1998

TABLET; ORAL

	EPIVIR-HBV			
+	GLAXO WELLCOME	100MG	N21003 001	DEC 08, 1998
+		100MG	N20564 002	DEC 08, 1998

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

	LEUCOVORIN CALCIUM			
AP +	ABBOTT	EQ 10MG BASE/ML	N40147 001	JUN 25, 1997
AP +	BEDFORD	EQ 200MG BASE/VIAL	N40056 001	MAY 23, 1995
	LEUCOVORIN CALCIUM PRESERVATIVE FREE			
AP +	ABBOTT	EQ 10MG BASE/ML	N40147 001	JUN 25, 1997

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	+ BEDFORD	EQ 200MG BASE/VIAL		N40056 001 MAY 23, 1995
AP	BIGMAR	EQ 10MG BASE/ML		N40286 001 FEB 26, 1999
AP		EQ 200MG BASE/VIAL		N40258 001 FEB 26, 1999
> ADD > AP > ADD >	GENSIA SICOR PHARMS	EQ 10MG BASE/ML		N40332 001 JUN 28, 1999

TABLET; ORAL
LEUCOVORIN CALCIUM

AB	INVAMED	EQ 15MG BASE		N75327 001 MAR 24, 1999
	WELLCOVORIN			
AB	GLAXO WELLCOME	EQ 5MG BASE		N18342 001 JUL 08, 1983
AB	*	EQ 25MG BASE		N18342 002 JUL 08, 1983
	@	EQ 5MG BASE		N18342 001 JUL 08, 1983
	@	EQ 25MG BASE		N18342 002 JUL 08, 1983

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
XOPENEX

	+ SEPRACOR	EQ 0.021% BASE		N20837 001 MAR 25, 1999
	+	EQ 0.042% BASE		N20837 002 MAR 25, 1999

LIDOCAINE

FILM, EXTENDED RELEASE; TRANSDERMAL
LIDODERM

	+ HIND HLTHCARE	700MG/12HR		N20612 001 MAR 19, 1999

LIDOCAINE; PRILOCAINE

AEROSOL, TOPICAL
EMLA

	+ ASTRA PHARMS	2.5%;2.5%		N20962 001 FEB 04, 1998

DISC; TOPICAL
EMLA

	+ ASTRA PHARMS	2.5%;2.5%		N20962 001 FEB 04, 1998

LISINOPRIL

TABLET; ORAL
ZESTRIL

	ZENECA	30MG		N19777 006 JAN 20, 1999

LITHIUM CARBONATE

CAPSULE; ORAL
LITHONATE

AB	SOLVAY	300MG		N16782 001
	@	300MG		N16782 001

TABLET; ORAL
LITHIUM CARBONATE

AB	PFIZER	300MG		N16834 001
AB	+	300MG		N16834 001
	LITHOTABS			
AB	+ SOLVAY	300MG		N16980 001
	@	300MG		N16980 001

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
IMODIUM

AB	+ JANSSEN	2MG		N17694 001
	@	2MG		N17690 001
AB	+ MCNEIL CONS	2MG		N17694 001
	@	2MG		N17690 001

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

		LOTEMAX			
> DLT >	+	PHARMOS	0.5%		N20841 001
> DLT >					MAR 09, 1998
> ADD >	@		0.5%		N20841 001
> ADD >					MAR 09, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

		ISOLYTE S PH 7.4 IN PLASTIC CONTAINER			
> DLT >		B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;		
> DLT >			370MG/100ML;530MG/100ML;500MG/100ML;		
> DLT >			12MG/100ML		N19006 001
> DLT >					APR 04, 1984
> ADD >	@		30MG/100ML;37MG/100ML;0.82MG/100ML;		
> ADD >			370MG/100ML;530MG/100ML;500MG/100ML;		
> ADD >			12MG/100ML		N19006 001
> ADD >					APR 04, 1984

MALATHION

LOTION; TOPICAL

		OVIDE			
> DLT >	@	MEDICIS	0.5%		N18613 001
> DLT >					AUG 02, 1982
> ADD >	+		0.5%		N18613 001
> ADD >					AUG 02, 1982

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

		VERMOX			
AB	+	JANSSEN	100MG		N17481 001
AB	+	MCNEIL CONS	100MG		N17481 001

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

		CYCRIN			
> DLT >		ESI	2.5MG		N81239 001
> DLT >					OCT 30, 1992
> DLT >					

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

		CYCRIN			
> DLT >		ESI	5MG		N81240 001
> DLT >					OCT 30, 1992
> DLT >					
> DLT >			10MG		N89386 001
> DLT >					SEP 09, 1987
> ADD >	@		2.5MG		N81239 001
> ADD >					OCT 30, 1992
> ADD >	@		5MG		N81240 001
> ADD >					OCT 30, 1992
> ADD >	@		10MG		N89386 001
> ADD >					SEP 09, 1987

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

		DEMEROL			
AP	+	ABBOTT	25MG/ML		N05010 007
AP	+		50MG/ML		N05010 002
AP	+		75MG/ML		N05010 009
AP	+		100MG/ML		N05010 003
AP	+	SANOFI	25MG/ML		N05010 007
AP	+		50MG/ML		N05010 002
AP	+		75MG/ML		N05010 009
AP	+		100MG/ML		N05010 003
		MEPERIDINE HCL			
AP	+	ABBOTT	10MG/ML		N88432 001
					AUG 16, 1984
AP		ASTRA PHARMS	10MG/ML		N81002 001
					JUL 30, 1993
AP		INTL MEDICATION	10MG/ML		N81309 001
					AUG 30, 1993
AP		MALLINCKRODT	10MG/ML		N40163 001
					MAY 12, 1997
AP		STERIS	10MG/ML		N73443 001
					MAR 17, 1992
		MEPERIDINE HCL PRESERVATIVE FREE			
AP	+	ABBOTT	10MG/ML		N88432 001
					AUG 16, 1984
AP		ASTRA PHARMS	10MG/ML		N81002 001
					JUL 30, 1993
AP		FAULDING	10MG/ML		N40305 001
					MAR 10, 1999
AP		INTL MEDICATION	10MG/ML		N81309 001
					AUG 30, 1993

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HCL PRESERVATIVE FREE

AP		MALLINCKRODT	10MG/ML	N40163 001 MAY 12, 1997
AP		STERIS	10MG/ML	N73443 001 MAR 17, 1992

SYRUP; ORAL

DEMEROL

AA	+	ABBOTT	50MG/5ML	N05010 005
AA	+	SANOFI	50MG/5ML	N05010 005

TABLET; ORAL

DEMEROL

AA	+	ABBOTT	50MG	N05010 001
AA	+		100MG	N05010 004
AA	+	SANOFI	50MG	N05010 001
AA	+		100MG	N05010 004

MEPERIDINE HCL

AA		AMIDE PHARM	50MG	N40331 001 MAY 28, 1999
AA			100MG	N40331 002 MAY 28, 1999

METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOPHAGE

	+	BRISTOL MYERS SQUIBB	500MG	N20357 001 MAR 03, 1995
			625MG	N20357 003 NOV 05, 1998
			750MG	N20357 004 NOV 05, 1998
			500MG	N20357 001 MAR 03, 1995
	@		625MG	N20357 003 NOV 05, 1998
	@		750MG	N20357 004 NOV 05, 1998

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE

AP		BIGMAR	EQ 25MG BASE/ML	N40263 001 FEB 26, 1999

METHOTREXATE PRESERVATIVE FREE

AP		BIGMAR	EQ 25MG BASE/ML	N40265 001 FEB 26, 1999
AP			EQ 1GM BASE/VIAL	N40266 001 FEB 26, 1999

METHOTREXATE SODIUM

	+	LEDERLE	EQ 1GM BASE/VIAL	N11719 009 APR 07, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+	LEDERLE	EQ 1GM BASE/VIAL	N11719 009 APR 07, 1988

TABLET; ORAL

METHOTREXATE SODIUM

				>ADD>
AB		DURAMED	EQ 2.5MG BASE	N40233 001 JUN 17, 1999
				>ADD>

METHOTRIMEPRAZINE

INJECTABLE; INJECTION

LEVOPROME

	+	IMMUNEX	20MG/ML	N15865 001
	@		20MG/ML	N15865 001

METHOXSALEN

INJECTABLE; INJECTION

UVADEX

	+	THERAKOS	0.02MG/ML	N20969 001 FEB 25, 1999

METOLAZONE

TABLET; ORAL

ZAROXOLYN

				>DLT>
		MEDEVA	2.5MG	N17386 001
				>ADD>
	+		2.5MG	N17386 001

MICONAZOLE NITRATE

> ADD > INSERT, CREAM; VAGINAL, TOPICAL
> ADD > MONISTAT DUAL- PAK
> ADD > + ADVANCED CARE PRODS 1.2GM,2% N20968 001
> ADD > JUN 30, 1999

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

AB	ALPHARMA US PHARM	200MG	N73508 001
			NOV 19, 1993
AB	NMC	200MG	N73508 001
			NOV 19, 1993

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL

> ADD >	+ DANBURY PHARMA	EQ 75MG BASE	N63065 002
> ADD >			JUN 10, 1999
AB	GLOBAL PHARM	EQ 50MG BASE	N65005 001
			MAR 23, 1999
AB		EQ 100MG BASE	N65005 002
			MAR 23, 1999

NADOLOL

TABLET; ORAL
CORGARD

AB	APOTHECON	20MG	N18063 005
			OCT 28, 1986
AB		40MG	N18063 001
AB		80MG	N18063 002
AB		120MG	N18063 003
AB	+	160MG	N18063 004
AB	BRISTOL MYERS SQUIBB	20MG	N18063 005
			OCT 28, 1986
AB		40MG	N18063 001
AB		80MG	N18063 002
AB		120MG	N18063 003
AB	+	160MG	N18063 004

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL

AB	AMIDE PHARM	50MG	N75274 001
			MAY 26, 1999

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN

AB	SIDMAK LABS CA	375MG	N75337 001
			MAY 26, 1999
AB		500MG	N75337 002
			MAY 26, 1999

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP

> DLT >	+ ELAN PHARM	11MG/24HR	N19983 001
> DLT >			JAN 28, 1992
> DLT >	+	22MG/24HR	N19983 002
> DLT >			JAN 28, 1992
> ADD >	@	11MG/24HR	N19983 001
> ADD >			JAN 28, 1992
> ADD >	@	22MG/24HR	N19983 002
> ADD >			JAN 28, 1992

NITROGLYCERIN

OINTMENT; TRANSDERMAL
NITROGLYCERIN

	ALTANA	2%	N87355 001
			JUL 08, 1988
	+	2%	N87355 001
			JUL 08, 1988

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC

	+ ASTRA PHARMS	10MG	N19810 003
			OCT 05, 1995

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
ASTRA PHARMS 10MG N19810 003 OCT 05, 1995

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ZOFRAN ODT
GLAXO WELLCOME EQ 4MG BASE N20781 001 JAN 27, 1999
\+ EQ 8MG BASE N20781 002 JAN 27, 1999

ORLISTAT

CAPSULE; ORAL
XENICAL
\+ ROCHE 120MG N20766 001 APR 23, 1999

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
ORPHENADRINE CITRATE
AB KIEL **100MG** **N40249 001** JAN 29, 1999

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE
AA MIKART **5MG/5ML** **N75039 001** JAN 29, 1999

TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL
>ADD< \+ ALZA 15MG N20897 003 JUN 22, 1999
>ADD<

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL
TERRAMYCIN
\+ PFIZER EQ 125MG BASE/5ML N60595 001
@ EQ 125MG BASE/5ML N60595 001

OXYTETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
TERRAMYCIN
\+ PFIZER EQ 250MG BASE/VIAL N60586 001
\+ EQ 500MG BASE/VIAL N60586 002
@ EQ 250MG BASE/VIAL N60586 001
@ EQ 500MG BASE/VIAL N60586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC
TERRAMYCIN W/ POLYMYXIN
\+ PFIZER EQ 5MG BASE/GM; 10,000 UNITS/GM N61841 001
@ EQ 5MG BASE/GM; 10,000 UNITS/GM N61841 001

TABLET; VAGINAL
TERRAMYCIN-POLYMYXIN
\+ PFIZER EQ 100MG BASE; 100,000 UNITS N61009 001
@ EQ 100MG BASE; 100,000 UNITS N61009 001

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PAXIL CR
\+ SMITHKLINE BEECHAM EQ 12.5MG BASE N20936 001 FEB 16, 1999
\+ EQ 25MG BASE N20936 002 FEB 16, 1999

PEMOLINE

TABLET; ORAL
CYLERT
AB ABBOTT **37.5MG** **N16832 002**

PEMOLINE

TABLET; ORAL

		CYLERT			
AB	+	ABBOTT	75MG		N16832 003
			18.75MG		N16832 001
			37.5MG		N16832 002
	+		75MG		N16832 003
	+		18.75MG		N16832 001
		PEMOLINE			
AB		COPLEY PHARM	37.5MG		N75030 001 JAN 29, 1999
AB			75MG		N75030 002 JAN 29, 1999
>ADD< AB		INVAMED	37.5MG		N75286 002 JUN 30, 1999
>ADD< AB			75MG		N75286 003 JUN 30, 1999

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

		PENTOXIFYLLINE			
AB		SIDMAK LABS NJ	400MG		N74874 001 MAY 25, 1999
>ADD< AB		TORPHARM	400MG		N75191 001 JUN 09, 1999
		PENTOXIL			
AB		UPSHER SMITH	400MG		N74962 001 MAR 31, 1999

PERINDOPRIL ERBUMINE

TABLET; ORAL

		ACEON			
>DLT<	@	HUESCHEN	2MG		N20184 001 DEC 30, 1993
>DLT<	@		4MG		N20184 002 DEC 30, 1993
>DLT<	@		8MG		N20184 003 DEC 30, 1993
>ADD<	@	SOLVAY	2MG		N20184 001 DEC 30, 1993
>ADD<	@		4MG		N20184 002 DEC 30, 1993
>ADD<	@		8MG		N20184 003 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

		PHENDIMETRAZINE TARTRATE			
>DLT< AA		MFG CHEMISTS	35MG		N85914 001
>ADD<	@		35MG		N85914 001
>DLT< AA		PVT FORM	35MG		N85697 001
>ADD<	@		35MG		N85697 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

		FASTIN			
AA	+	SMITHKLINE BEECHAM	30MG		N17352 001
	@		30MG		N17352 001
		PHENTERMINE HCL			
AA		EON	30MG		N86945 001 JUL 20, 1983
AA	+		30MG		N86945 001 JUL 20, 1983

POLYETHYLENE GLYCOL 3350

POWDER FOR RECONSTITUTION; ORAL

		MIRALAX			
	+	BRAINTREE	17GM/SCOOPFUL		N20698 001 FEB 18, 1999

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

		TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE			
AT		ALCON	10,000 UNITS/ML; EQ 1MG BASE/ML		N64211 001 APR 13, 1998
AT		FALCON PHARMS	10,000 UNITS/ML; EQ 1MG BASE/ML		N64211 001 APR 13, 1998

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		MICRO-K			
AB		KV PHARM	8MEQ		N18238 001
AB		ROBINS AH	8MEQ		N18238 001

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		MICRO-K 10		
AB	+	KV PHARM	10MEQ	N18238 002 MAY 14, 1984
AB	+	ROBINS AH	10MEQ	N18238 002 MAY 14, 1984

GRANULE, FOR RECONSTITUTION ER; ORAL

		MICRO-K LS		
	@	KV PHARM	20MEQ/PACKET	N19561 003 AUG 26, 1988
	@	ROBINS AH	20MEQ/PACKET	N19561 003 AUG 26, 1988

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

		THAM-E		
	+	ABBOTT	370MG/VIAL;1.75GM/VIAL; 36GM/VIAL	N13025 001
	@		370MG/VIAL;1.75GM/VIAL; 36GM/VIAL	N13025 001

POTASSIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL

		POTASSIUM CITRATE		
	@	MISSION PHARMA	10MEQ/PACKET	N19647 002 OCT 13, 1988
	@		20MEQ/PACKET	N19647 001 OCT 13, 1988
	@	UNIV TX	10MEQ/PACKET	N19647 002 OCT 13, 1988
	@		20MEQ/PACKET	N19647 001 OCT 13, 1988

PREDNISOLONE

SYRUP; ORAL

		PREDNISOLONE		
AA		HALSEY	15MG/5ML	N40287 001 MAY 28, 1999
AA		UDL	15MG/5ML	N40323 001 MAY 13, 1999

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

		ECONOPRED PLUS		
AB		ALCON	1%	N17469 001
AB		FALCON PHARMS	1%	N17469 001

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

		HYDELTRASOL		
	+	MERCK	EQ 20MG PHOSPHATE/ML	N11583 002
	@		EQ 20MG PHOSPHATE/ML	N11583 002

PROBENECID

TABLET; ORAL

		BENEMID		
AB	+	MERCK	500MG	N07898 004
	@		500MG	N07898 004
		PROBENECID		
AB		MYLAN	500MG	N84211 002
AB	+		500MG	N84211 002

PROPOFOL

INJECTABLE; INJECTION

		DIPRIVAN		
AB	+	ZENECA	10MG/ML	N19627 002 JUN 11, 1996
	+		10MG/ML	N19627 002 JUN 11, 1996
		PROPOFOL		
AB		GENSIA SICOR PHARMS	10MG/ML	N75102 001 JAN 04, 1999

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

		RANITIDINE HCL		
AB		GRANUTEC PHARMS	EQ 150MG BASE	N74488 001 JUL 31, 1997
AB			EQ 300MG BASE	N74488 002 JUL 31, 1997

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

AB	NOVOPHARM NC	EQ 150MG BASE	N74488 001 JUL 31, 1997	
AB		EQ 300MG BASE	N74488 002 JUL 31, 1997	
AB	PAR PHARM	EQ 150MG BASE	N75180 001 JAN 28, 1999	
AB		EQ 300MG BASE	N75180 002 JAN 28, 1999	

RISPERIDONE

TABLET; ORAL
RISPERDAL

	JANSSEN	0.25MG	N20272 008 MAY 10, 1999
+		0.5MG	N20272 007 JAN 27, 1999

RITONAVIR

CAPSULE; ORAL
NORVIR

>ADD> >ADD>	ABBOTT	100MG	N20945 001 JUN 29, 1999	>ADD> >ADD> >DLT> >DLT>

SOLUTION; ORAL
NORVIR

	ABBOTT	80MG/ML	N20659 001 MAR 01, 1996
+		80MG/ML	N20659 001 MAR 01, 1996

ROFECOXIB

SUSPENSION; ORAL
VIOXX

	MERCK	12.5MG/5ML	N21052 001 MAY 20, 1999
+		25MG/5ML	N21052 002 MAY 20, 1999

ROFECOXIB

TABLET; ORAL
VIOXX

	MERCK	12.5MG	N21042 001 MAY 20, 1999
+		25MG	N21042 002 MAY 20, 1999

ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDIA

	SMITHKLINE BEECHAM	EQ 2MG BASE	N21071 002 MAY 25, 1999
		EQ 4MG BASE	N21071 003 MAY 25, 1999
+		EQ 8MG BASE	N21071 004 MAY 25, 1999

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE

>ADD> >ADD>	+ HLR	200MG	N20828 001 NOV 07, 1997	
>DLT> >DLT>	+ ROCHE	200MG	N20828 001 NOV 07, 1997	

SAQUINAVIR MESYLATE

CAPSULE; ORAL
INVIRASE

>ADD> >ADD>	+ HLR	EQ 200MG BASE	N20628 001 DEC 06, 1995	
>DLT> >DLT>	+ ROCHE	EQ 200MG BASE	N20628 001 DEC 06, 1995	

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
ELDEPRYL

	@ SOMERSET	5MG	N19334 001 JUN 05, 1989

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HCL

AB	+	SOMERSET	5MG	N19334 001 JUN 05, 1989	

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 10%

> ADD >	AP	+	FRESENIUS KABI	10%	N17643 001
> DLT >	AP	+	PHARMACIA AND UPJOHN	10%	N17643 001

INTRALIPID 20%

> ADD >	AP	+	FRESENIUS KABI	20%	N18449 001
> DLT >	AP	+	PHARMACIA AND UPJOHN	20%	N18449 001

INTRALIPID 30%

> ADD >	AP	+	FRESENIUS KABI	30%	N19942 001 DEC 30, 1993
> ADD >					
> DLT >	AP	+	PHARMACIA AND UPJOHN	30%	N19942 001 DEC 30, 1993
> DLT >					

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE

AB	PUREPAC PHARM	25MG	N87998 001 OCT 14, 1983
@		25MG	N87998 001 OCT 14, 1983

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SODIUM SULFACETAMIDE

AT	AKORN	10%	N83021 001
AT		15%	N83021 002
AT		30%	N83021 003
@		10%	N83021 001
@		15%	N83021 002
@		30%	N83021 003

SULFACETAMIDE SODIUM

AT	AKORN	10%	N40215 001 MAY 25, 1999
AT		30%	N40216 001 MAY 25, 1999

TACROLIMUS

CAPSULE; ORAL
PROGRAF

+	FUJISAWA HLTHCARE	EQ 1MG BASE	N50708 001 APR 08, 1994
		EQ 0.5MG BASE	N50708 003 AUG 24, 1998
		EQ 1MG BASE	N50708 001 APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
A-N STANNOUS AGGREGATED ALBUMIN

@	NORTH AM CHEMS	N/A	N17916 001
@	SYNCOR PHARMS	N/A	N17916 001

PULMOLITE

BS	CIS	N/A	N17776 001
BS	DUPONT PHARMS	N/A	N17776 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION
MICROLITE

	CIS	N/A	N18263 001 MAR 25, 1983
	DUPONT PHARMS	N/A	N18263 001 MAR 25, 1983

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE

	CIS	N/A	N18467 001 MAR 16, 1982
	DUPONT PHARMS	N/A	N18467 001 MAR 16, 1982

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
OSTEOLITE

AP	CIS	N/A	N17972 001
AP	DUPONT PHARMS	N/A	N17972 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION
PYROLITE

		CIS	N/A	N17684 001
		DUPONT PHARMS	N/A	N17684 001

TERBUTALINE SULFATE

INJECTABLE; INJECTION
BRETHINE

AP	+	NOVARTIS	1MG/ML	N18571 001
	+		1MG/ML	N18571 001

BRICANYL

AP	+	HOECHST MARION RSSL	1MG/ML	N17466 001
	@		1MG/ML	N17466 001

TABLET; ORAL
BRETHINE

> DLT >	BP	NOVARTIS	2.5MG	N17849 001
> DLT >	BP	+	5MG	N17849 002
> ADD >			2.5MG	N17849 001
> ADD >		+	5MG	N17849 002

BRICANYL

> DLT >	BP	HOECHST MARION RSSL	2.5MG	N17618 001
> DLT >	BP		5MG	N17618 002
> ADD >		@	2.5MG	N17618 001
> ADD >		@	5MG	N17618 002

TERIPARATIDE ACETATE

INJECTABLE; INJECTION
PARATHAR

	+	RHONE POULENC RORER	200 UNITS/VIAL	N19498 001 DEC 23, 1987
	@		200 UNITS/VIAL	N19498 001 DEC 23, 1987

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL

AB		PUREPAC PHARM	250MG	N60290 001
AB			500MG	N60290 002
	@		250MG	N60290 001
	@		500MG	N60290 002

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYN

AB		PFIPHARMECS	250MG	N60082 003
AB			500MG	N60082 004
	@		250MG	N60082 003
	@		500MG	N60082 004

THEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER			
@	B BRAUN	40MG/100ML	N19083 001 NOV 07, 1984
@	MCGAW	40MG/100ML	N19083 001 NOV 07, 1984
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER			
@	B BRAUN	80MG/100ML	N19083 002 NOV 07, 1984
@	MCGAW	80MG/100ML	N19083 002 NOV 07, 1984
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER			
@	B BRAUN	160MG/100ML	N19083 003 NOV 07, 1984
@	MCGAW	160MG/100ML	N19083 003 NOV 07, 1984

TABLET, EXTENDED RELEASE; ORAL
SUSTAIRE

BC		ROERIG	100MG	N85665 001
BC			300MG	N85665 002
	@		100MG	N85665 001
	@		300MG	N85665 002

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL

AA		ALPHARMA	EQ 5MG BASE/ML	N70969 001 OCT 16, 1987
	@		EQ 5MG BASE/ML	N70969 001 OCT 16, 1987

TIAGABINE HYDROCHLORIDE

TABLET; ORAL
GABITRIL
+ ABBOTT 2MG N20646 005 APR 16, 1999

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID
> DLT > @ ROCHE 125MG N19979 001 MAR 24, 1993
> DLT > + 250MG N19979 002 OCT 31, 1991
> ADD > @ SYNTEX 125MG N19979 001 MAR 24, 1993
> ADD > + 250MG N19979 002 OCT 31, 1991

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC
TIMOLOL MALEATE
AB ALCON EQ 0.25% BASE N20963 001 OCT 21, 1998
AB EQ 0.5% BASE N20963 002 OCT 21, 1998
AB FALCON PHARMS EQ 0.25% BASE N20963 001 OCT 21, 1998
AB EQ 0.5% BASE N20963 002 OCT 21, 1998

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE
AT ADV REMEDIES EQ 0.5% BASE N74466 001 MAR 25, 1997
AT AKORN EQ 0.5% BASE N74466 001 MAR 25, 1997
AT ALCON EQ 0.25% BASE N74261 001 APR 28, 1995
AT EQ 0.5% BASE N74262 001 APR 28, 1995
@ FALCON PHARMS EQ 0.25% BASE N74261 001 APR 28, 1995
@ EQ 0.5% BASE N74262 001 APR 28, 1995

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBREX
AT + ALCON 0.3% N50541 001
AT + FALCON PHARMS 0.3% N50541 001

TRETINOIN

SOLUTION; TOPICAL
TRETINOIN
AT MORTON GROVE 0.05% N75260 001 JAN 25, 1999

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
ARISTOCORT
AT FUJISAWA HLTHCARE 0.025% N83017 003
AT 0.1% N83016 004
AT 0.5% N83015 002
AT LEDERLE 0.025% N83017 003
AT 0.1% N83016 004
AT 0.5% N83015 002
ARISTOCORT A
AT FUJISAWA HLTHCARE 0.025% N83017 004
AT 0.025% N88818 001 OCT 16, 1984
AT 0.1% N83016 005
AT 0.1% N88819 001 OCT 16, 1984
AT 0.5% N83015 003
AT 0.5% N88820 001 OCT 16, 1984
AT LEDERLE 0.025% N83017 004
AT 0.025% N88818 001 OCT 16, 1984
AT 0.1% N83016 005
AT 0.1% N88819 001 OCT 16, 1984
AT 0.5% N83015 003
AT 0.5% N88820 001 OCT 16, 1984

GEL; TOPICAL
ARISTOGEL
@ FUJISAWA HLTHCARE 0.1% N83380 001

TRIAMCINOLONE ACETONIDE

GEL; TOPICAL
ARISTOGEL
@ LEDERLE 0.1% N83380 001

OINTMENT; TOPICAL
ARISTOCORT
AT FUJISAWA HLTHCARE 0.1% N80750 004
AT 0.5% N80745 002
AT LEDERLE 0.1% N80750 004
AT 0.5% N80745 002

ARISTOCORT A
AT FUJISAWA HLTHCARE 0.1% N80750 003
AT + 0.5% N80745 003
@ 0.5% N88781 001
OCT 05, 1984
AT LEDERLE 0.1% N80750 003
AT + 0.5% N80745 003
@ 0.5% N88781 001
OCT 05, 1984

TRIAMCINOLONE DIACETATE

SYRUP; ORAL
ARISTOCORT
FUJISAWA HLTHCARE 2MG/5ML N11960 004
LEDERLE 2MG/5ML N11960 004

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL
SULFA-TRIPLE #2
AB + GLOBAL PHARM 167MG;167MG;167MG N80079 001
@ 167MG;167MG;167MG N80079 001
TRIPLE SULFOID
AB PAL PAK 167MG;167MG;167MG N80094 001
+ 167MG;167MG;167MG N80094 001

UREA, C-13

POWDER FOR RECONSTITUTION; ORAL
PYLORI-CHEK BREATH TEST
+ ALIMENTERICS 100MG/VIAL N20900 001
FEB 04, 1999

VALRUBICIN

SOLUTION;
VALSTAR PRESERVATIVE FREE
+ ANTHRA 40MG/ML N20892 001
SEP 25, 1998

SOLUTION; INTRAVESICAL
VALSTAR PRESERVATIVE FREE
+ ANTHRA 40MG/ML N20892 001
SEP 25, 1998

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERAPAMIL HCL
AB MYLAN 120MG N75138 001
APR 20, 1999
AB 180MG N75138 002
APR 20, 1999
AB 240MG N75138 003
APR 20, 1999

VERELAN
+ ELAN 120MG N19614 001
MAY 29, 1990
+ 180MG N19614 003
JAN 09, 1992
+ 240MG N19614 002
MAY 29, 1990
AB + ELAN PHARM 120MG N19614 001
MAY 29, 1990
AB + 180MG N19614 003
JAN 09, 1992
AB + 240MG N19614 002
MAY 29, 1990

TABLET, EXTENDED RELEASE; ORAL
VERAPAMIL HCL
AB DURAMED 120MG N75072 001
MAY 25, 1999
AB 240MG N75072 003
MAY 25, 1999

WARFARIN SODIUM

TABLET; ORAL
COUMADIN
AB + DUPONT MERCK 2MG N09218 013

WARFARIN SODIUM

TABLET; ORAL

		COUMADIN		
AB		DUPONT MERCK	2MG	N09218 013
AB			2.5MG	N09218 018
AB	+		2.5MG	N09218 018
AB			5MG	N09218 007
AB	+		5MG	N09218 007

ACETAMINOPHEN

SUPPOSITORY; RECTAL
ACEPHEN

>_DLT_>	+	G AND W LABS	120MG	N18060 001	>_ADD_>
>_DLT_>	+		325MG	N18060 003	>_ADD_>
>_DLT_>				DEC 18, 1986	
>_DLT_>	+		650MG	N18060 002	
>_ADD_>			120MG	N18060 001	
>_ADD_>			325MG	N18060 003	
>_ADD_>				DEC 18, 1986	
>_ADD_>			650MG	N18060 002	

ACETAMINOPHEN
ASCENT PEDS

		120MG	N18337 003	
			SEP 12, 1983	
		325MG	N18337 002	
>_ADD_>	+	650MG	N18337 001	
		UPSHER SMITH	120MG	N18337 003
			SEP 12, 1983	
		325MG	N18337 002	
>_DLT_>		650MG	N18337 001	

INFANTS' FEVERALL

>_ADD_>	ASCENT PEDS	80MG	N18337 004	
>_ADD_>			AUG 26, 1992	
>_DLT_>	UPSHER SMITH	80MG	N18337 004	
>_DLT_>			AUG 26, 1992	

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CONTAC

+	SMITHKLINE	8MG;75MG	N18099 001
@		8MG;75MG	N18099 001

PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE

	CENT PHARMS	8MG;75MG	N18809 001
			MAY 07, 1984
+		8MG;75MG	N18809 001
			MAY 07, 1984

TABLET, EXTENDED RELEASE; ORAL
CONTAC

>_DLT_>		NOVARTIS	12MG;75MG	N19613 001
>_DLT_>				JUN 13, 1986
>_ADD_>	+		12MG;75MG	N19613 001
>_ADD_>				JUN 13, 1986

TRIAMINIC-12

+	NOVARTIS	12MG;75MG	N18115 001
@		12MG;75MG	N18115 001

CIMETIDINE

TABLET; ORAL
CIMETIDINE

>_ADD_>	ZENITH GOLDLINE	200MG	N75345 001	
>_ADD_>			JUN 16, 1999	

CLOTRIMAZOLE

CREAM; TOPICAL
LOTRIMIN AF

	SCHERING PLOUGH	1%	N17619 002
			OCT 27, 1989

LOTION; TOPICAL
LOTRIMIN AF

	SCHERING	1%	N18813 002
			OCT 27, 1989

SOLUTION; TOPICAL
LOTRIMIN AF

	SCHERING PLOUGH	1%	N17613 002
			OCT 27, 1989

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION
MEDIHALER-EPI

+	3M	0.3MG/INH	N10374 003
@		0.3MG/INH	N10374 003

IBUPROFEN

SUSPENSION; ORAL
IBUPROFEN

	ALPHARMA	100MG/5ML	N74916 001
			APR 30, 1999

TABLET; ORAL
IBUPROFEN

	LNK	200MG	N75010 001
			MAR 01, 1999
		200MG	N75139 001
			MAR 01, 1999
	NORTON HN	200MG	N71144 001
			JAN 20, 1987

IBUPROFEN

TABLET; ORAL

IBUPROFEN			
NORTON HN	200MG	N72901 001	> ADD >
		DEC 19, 1991	> ADD >
	200MG	N72903 001	> ADD >
		DEC 19, 1991	> ADD >
ZENITH GOLDLINE	200MG	N71144 001	
		JAN 20, 1987	
	200MG	N72901 001	
		DEC 19, 1991	
	200MG	N72903 001	
		DEC 19, 1991	
JUNIOR STRENGTH IBUPROFEN			
PERRIGO	100MG	N75367 001	
		APR 22, 1999	

IBUPROFEN POTASSIUM

CAPSULE; ORAL

PROVEL		
* NOVARTIS	200MG	N20402 001
		APR 20, 1995
+ WHITEHALL ROBINS	200MG	N20402 001
		APR 20, 1995

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK		
ALPHARMA US PHARM	2%,200MG	N74926 001
		APR 16, 1999
MICONAZOLE NITRATE COMBINATION PACK		
PERRIGO	2%,200MG	N75329 001
		APR 20, 1999

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE			
ALPHARMA US PHARM	100MG	N73507 001	> ADD >
		NOV 19, 1993	> ADD >
NMC	100MG	N73507 001	> ADD >
		NOV 19, 1993	

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

PROSTEP		
+ ELAN PHARM	11MG/24HR	N19983 003
		DEC 23, 1998
+	22MG/24HR	N19983 004
		DEC 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX		
CIRCA	EQ 2MG BASE	N74507 001
		MAR 15, 1999
	EQ 4MG BASE	N74707 001
		MAR 19, 1999

NONOXYNOL-9

SPONGE; VAGINAL

TODAY		
@ ALLENDALE PHARMS	1GM	N18683 001
		APR 01, 1983
@ WHITEHALL ROBINS	1GM	N18683 001
		APR 01, 1983

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HCL		
PERRIGO	120MG	N75153 001
		FEB 26, 1999

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HCL		
NOVOPHARM	EQ 75MG BASE	N75094 001
		JUN 21, 1999
RANBAXY	EQ 75MG BASE	N75132 001
ZANTAC 75		
* GLAXO WELLCOME	EQ 75MG BASE	N20520 001
		DEC 19, 1995

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
ZANTAC 75
+ WARNER LAMBERT EQ 75MG BASE N20520 001
DEC 19, 1995

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL
LAMISIL
+ NOVARTIS 1% N20980 001
MAR 09, 1999

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 6 JUN '99

NO JUNE 1999 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
June 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
111Indium pentetreotide TN= SomatoTher	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation 1600 Canal St. 10th Floor New Orleans, LA 70112 DD=06/10/1999
166Ho-DOTMP TN=	Treatment of multiple myeloma.	NeoRx Corporation 410 W. Harrison Seattle, WA 98119 DD=02/10/1999
6-hydroxymethylacylfulvene TN=	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	MGI Pharma, Inc. Suite 300E, Opus Center 9900 Bren Road East Minnetonka, MN 55343 DD=04/06/1999
Alitretinoin TN= Panretin	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998 MA=02/02/1999
Amifostine TN= Ethyol	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998 MA=06/24/1999

Orphan Product Designations and Approvals List
June 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized TN= Humate-P	Treatment and prevention of bleeding in hemophilia A (classical hemophilia) in adult patients; and treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate in adult and pediatric patients.	Centeon Pharma GmbH Emil-von-Behring-Strase 76 35041 Marburg Germany, DD=10/16/1992 MA=04/01/1999
Atovaquone TN= Mepron	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development 5 Moore Drive PO Box 13398 Research Triangle Park, NC 27709 DD=08/14/1991 MA=01/05/1999
Autologous DNP-conjugated tumor vaccine TN= M-Vax	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc. 4520 Main St. Suite 930 Kansas City, MO 64111 DD=02/23/1999
Beraprost TN=	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	United Therapeutics Corporation 68 T.W. Alexander Drive, PO Box 14186 Research Triangle Park, NC 27709 DD=04/29/1999

Orphan Product Designations and Approvals List
June 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Bexarotene TN= Targretin	Treatment of cutaneous T-cell lymphoma.	Ligand Pharmaceuticals, Inc. 10275 Science Center Dr. San Diego, CA 92121 DD=06/18/1999
Bleomycin TN= Blenoxane	Treatment of pancreatic cancer.	Genetronics, Inc. 11199 Sorrento Valley Rd. San Diego, CA 92121 DD=02/09/1999
Busulfan TN= Busulfex	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=07/28/1994 MA=02/04/1999
CT-2584 mesylate TN=	Treatment of adult soft tissue sarcoma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Suite 400 Seattle, WA 98119 DD=04/16/1999
CT-2584 mesylate TN=	Treatment of malignant mesothelioma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Seattle, WA 98119 DD=04/16/1999
Coagulation factor VIIa (recombinant) TN= NovoSeven	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk Pharmaceuticals, Inc. 100 Overlook Center Suite 200 Princeton, NJ 08540 DD=06/06/1988 MA=03/25/1999

Orphan Product Designations and Approvals List
June 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Cytarabine liposomal TN= DepoCyt	Treatment of neoplastic meningitis.	DepoTech Corporation 10450 Science Center Drive San Diego, CA 92121 DD=06/02/1993 MA=04/01/1999
Decitabine TN=	Treatment of myelodysplastic syndromes.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem, The Netherlands DD=03/08/1999
Decitabine TN=	Treatment of chronic myelogenous leukemia.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem, The Netherlands DD=03/08/1999
Denileukin diftitox TN= Ontak	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	Seragen, Inc. 97 South Street Hopkinton, MA 01748 DD=08/21/1996 MA=02/05/1999
Doxorubicin liposome TN= Doxil	Treatment of ovarian cancer.	Alza Corporation 1550 Plymouth St. PO Box 7210 Mountain View, CA 94039 DD=11/04/1998 MA=06/28/1999
Epoprostenol TN= Flolan	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	Glaxo Wellcome Inc. Five Moore Dr. PO Box 13398 Research Triangle Park, NC 27709 DD=03/22/1999

Orphan Product Designations and Approvals List
June 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Etanercept TN= Enbrel	Treatment of Wegener's granulomatosis.	Stone, MD, MPH, John H. Johns Hopkins Vasculitis Center, Division of Rheumatology 1830 East Monument St., Suite 7500 Baltimore, MD 21205 DD=04/06/1999
Fluoxetine TN= Prozac	Treatment of autism.	Hollander, MD, Eric Mt. Sinai School of Medicine, Dept. of Psychiatry Box 1230, One Gustave L. Levy Place New York, NY 10029 DD=04/30/1999
Humanized MAb (IDEC-131) to CD40L TN=	Treatment of systemic lupus erythematosus.	Idec Pharmaceuticals Corporation 3030 Callan Rd. San Diego, CA 92121 DD=02/09/1999
Interferon beta-1a (recombinant human) TN= Avonex	Treatment of pulmonary fibrosis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=01/07/1999
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B) TN= 131IchTNT-1	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Techniclone Corporation 14282 Franklin Ave. Tustin, CA 92780 DD=02/12/1999

Orphan Product Designations and Approvals List
June 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Japanese encephalitis vaccine (live, attenuated) TN=	Prevention of Japanese encephalitis.	Boran Pharmaceuticals 3F, Koryo Academytel, 437-3 Ahyun-Dong, Mapo-Gu, Seoul 121-010 South Korea, DD=05/19/1999
L-5-hydroxytryptophan TN=	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc. 311 Bonnie Circle P.O. Box 1900 Corona, CA 91718 DD=01/20/1999
Lactic acid TN= Aphthaid	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc. SUNY Farmingdale Conklin Hall Farmingdale, NY 11735 DD=06/29/1999
Lidocaine patch 5% TN= Lidoderm Patch	For relief of allodynia (painful hypersensitivity), and chronic pain in post-herpetic neuralgia.	Hind Health Care, Inc. 3707 Williams Rd., Suite 101 San Jose, CA 95117 DD=10/24/1995 MA=03/19/1999
Lisofylline TN=	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc. 201 Elliot Ave. W., Suite 400 Seattle, WA 98119 DD=06/10/1999
Marijuana TN=	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc. 3 Francis St. Belmont, MA 02478 DD=05/25/1999

Orphan Product Designations and Approvals List
June 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Murine MAb to polymorphic epithelial mucin, human milk fat globule 1 TN= Theragyn	Adjuvant treatment of ovarian cancer.	Antisoma West Africa House Hanger Lane London W5 3QR, UK DD=03/22/1999
N-acetylgalactosamine-4-sulfatase, recombinant human TN=	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc. 11 Pimental Court Novato, CA 94949 DD=02/17/1999
Parovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine TN= MEDI-491	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg, MD 20878 DD=05/07/1999
Pegylated arginine deiminase TN= Hepacid	Treatment of hepatocellular carcinoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=03/26/1999
Pegylated arginine deiminase TN= Melanocid	Treatment of invasive malignant melanoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=04/12/1999
Recombinant human C1-esterase inhibitor TN=	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel, Belgium DD=02/23/1999

Orphan Product Designations and Approvals List
June 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant human C1-esterase inhibitor TN=	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel, Belgium DD=02/23/1999
Recombinant human insulin-like growth factor-I/insulin -like growth factor binding protein-3 TN=	Treatment of major burns that require hospitalization.	Celtrix Pharmaceuticals, Inc. 3055 Patrick Hendry Dr. Santa Clara, CA 95054 DD=06/15/1999
Recombinant human nerve growth factor TN=	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=04/16/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of solid organ transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Rifalazil TN=	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=04/13/1999

Orphan Product Designations and Approvals List
June 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
SCH 58500 TN=	Treatment of primary ovarian cancer.	Schering Corporation 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=04/12/1999
Sodium 1,3-propanedisulfonate TN=	Treatment of secondary amyloidosis.	Neurochem, Inc. 7220 Frederick Banting, Suite 100 Saint-Laurent, Quebec Canada H4S 2A1 DD=04/06/1999
Sodium dichloroacetate TN= Ceresine	Treatment of severe head injury.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=06/14/1999
Synthetic human secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 1550 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic human secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic human secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic porcine secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999

Orphan Product Designations and Approvals List
June 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Synthetic porcine secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Thalidomide TN= Thalomid	Treatment of Crohn's disease.	Celgene Corporation 7 Powder Horn Dr. Warren, NJ 07059 DD=04/06/1999
Tobramycin TN= Tobi	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=06/18/1999
Transgenic human alpha 1 antitrypsin TN=	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K. DD=05/19/1999

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JUNE 1999 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 19TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

NP* **NEW PRODUCT (MINT FLAVORED)**

REFERENCES

NEW DOSING SCHEDULE

D-50 **INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS**

NEW INDICATION

I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C

I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER

I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN

I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN

I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)

I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)

I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY

I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION

I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES FOUR AND ABOVE

I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)

I-261 TREATMENT OF SOCIAL ANXIETY DISORDER

I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12

I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY

PATENT USE CODE

U-254 USE OF AGGRASTAT IN COMBINATION WITH HEPARIN

U-255 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-256	TREATMENT OF HIV INFECITON IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN.
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN.
U-265	USE AS A LAXATIVE
U-266	OSTEOARTHRITIS
U-267	METHOD FOR PREVENTING HEARTBURN

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020482 004	ACARBOSE;PRECOSE				I-252	SEP 29, 2001
						I-253	SEP 29, 2001
	020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA				I-262	JUN 02, 2002
	020886 001	ALITRETINOIN;PANRETIN				ODE	FEB 02, 2006
						NCE	FEB 02, 2004
>ADD>	020221 001	AMIFOSTINE;ETHYOL				ODE	JUN 24, 2006
	021007 001	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021007 002	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021039 001	AMPRENAVIR;AGENERASE	5585397	DEC 17, 2013		NCE	APR 15, 2004
	020500 001	ATOVAQUONE;MEPRON				ODE	JAN 05, 2006
						I-255	JAN 05, 2002
	020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			
	020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			
	020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
			5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
	020313 002	CALCITONIN, SALMON;MIACALCIN	5759565	JUN 02, 2015			
	020998 001	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			
	020998 002	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			
	020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NS	MAY 24, 2002
			5177080	NOV 26, 2011			
	020638 001	CIDOFOVIR;VISTIDE	5142051	JUN 26, 2010			
>ADD>	020863 001	CILOSTAZOL;PLETAL	4277479	AUG 29, 1999		NCE	JAN 15, 2004
>ADD>	020863 002	CILOSTAZOL;PLETAL	4277479	AUG 29, 1999		NCE	JAN 15, 2004
	020767 001	CISAPRIDE MONOHYDRATE;PROPULSID QUICKSOLV	5648093	JUL 15, 2014			
	021041 001	CYTARABINE;DEPOCYT				ODE	APR 01, 2006
						NP	APR 01, 2002
	020287 001	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 003	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 004	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	017922 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 003	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
>ADD>	074752 001	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 19, 1999
>ADD>	074752 003	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 19, 1999
>ADD>	074752 004	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 19, 1999
>ADD>	020449 001	DOCETAXEL;TAXOTERE	4814470	MAY 14, 2010			
>ADD>			5438072	NOV 22, 2013			
>ADD>			5698582	JUL 03, 2012			
>ADD>			5714512	JUL 03, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	050718 001	DOXORUBICIN HYDROCHLORIDE;DOXIL				ODE	JUN 28, 2006
	020972 001	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256		
			5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
	020972 002	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256		
			5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
	020972 003	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
			5811423	AUG 07, 2012	U-256		
	020375 001	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 002	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 003	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 004	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
	020908 001	ESTRADIOL;VAGIFEM				NP	MAR 26, 2002
	020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NP	MAR 24, 2002
	020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NP	MAR 24, 2002
	020527 003	ESTROGENS, CONJUGATED;PREMPRO 14/14	4826831	MAY 02, 2006			
			5547948	JAN 17, 2015			
	020363 001	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
	020363 003	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
	020325 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-267		
>ADD>	020801 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-267		
	019304 002	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
	020747 001	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 002	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 003	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 004	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 005	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 006	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020955 001	FERRIC SODIUM GLUCONATE;FERRLECIT				NCE	FEB 18, 2004
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5855912	FEB 28, 2015			
			5738872	FEB 28, 2015			
	020788 001	FINASTERIDE;PROPECIA	5571817	NOV 05, 2013	U-259		
			5886184	NOV 19, 2012			
	020180 001	FINASTERIDE;PROSCAR	4760071	JUN 19, 2006	U-262		
			5886184	NOV 19, 2012			
			4377584	MAR 22, 2000	U-261		
	020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
			4626549	DEC 02, 2003			
	020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
			4626549	DEC 02, 2003			
	020121 001	FLUTICASONE PROPIONATE;FLONASE				I-258	DEC 11, 2001
	020882 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		
	020882 002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		
	020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
>ADD>	020491 001	IBUTILIDE FUMARATE;CORVERT				D-50	MAY 13, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020083 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020657 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020966 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
			4267179	JUN 23, 2000			
	020564 001	LAMIVUDINE;EPIVIR	5905082	MAY 18, 2016			
	020564 002	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
			5532246	JUL 02, 2013	U-250		
			5905082	MAY 18, 2016			
	020596 002	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
			5532246	JUL 02, 2013	U-250		
	020764 001	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 002	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 003	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020597 001	LATANOPROST;XALATAN	5296504	MAR 22, 2011	U-260		
			5422368	MAR 22, 2011	U-260		
			4599353	JUL 28, 2006	U-260		
>ADD>	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX				NP	MAR 25, 2002
>ADD>	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX				NP	MAR 25, 2002
	019941 001	LIDOCAINE;EMLA				I-260	MAR 11, 2002
	020612 001	LIDOCAINE;LIDODERM				ODE	MAR 19, 2006
	019777 006	LISINOPRIL;ZESTRIL	4374829	DEC 30, 2001			
>ADD>	019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2005		I-250	MAR 11, 2002
>ADD>	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2005		I-250	MAR 11, 2002
>ADD>	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2005		I-250	MAR 11, 2002
	020969 001	METHOXSALEN;UVADEX	4845075	APR 11, 2009		NP	FEB 25, 2002
			5036102	APR 11, 2009			
>ADD>	020968 001	MICONAZOLE NITRATE;MONISTAT DUAL- PAK				NP	JUN 30, 2002
	020682 001	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020682 002	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020682 003	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020717 001	MODAFINIL;PROVIGIL	4177290	MAR 09, 1999			
			5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		
	020717 002	MODAFINIL;PROVIGIL	4177290	MAR 09, 1999			
			5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		
	018612 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020066 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020385 001	NICOTINE;NICOTROL	5656255	AUG 12, 2014			
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020766 001	ORLISTAT;XENICAL				NCE	APR 23, 2004
>ADD>	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	4612008	SEP 16, 2003		NP	DEC 16, 2001
>ADD>			4519801	JUL 12, 2002			
>ADD>			5912268	MAY 22, 2015			
			4783337	SEP 16, 2003			
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			5840754	MAY 22, 2015			
>ADD>	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	4612008	SEP 16, 2003		NP	DEC 16, 2001
>ADD>			4519801	JUL 12, 2002			
>ADD>			5912268	MAY 22, 2015			
			5840754	MAY 22, 2015			
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
>ADD>	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	5912268	MAY 22, 2015		NP	DEC 16, 2001
>ADD>			4612008	SEP 16, 2003			
>ADD>			4519801	JUL 12, 2002			
	020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			
	020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	5710183	JUL 14, 2015	U-265	NP	FEB 18, 2002
>ADD>	019627 002	PROPOFOL;DIPRIVAN	5908869	MAR 22, 2015	U-270		
	075102 001	PROPOFOL;PROPOFOL				PC	OCT 16, 1999
	020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
>ADD>	075094 001	RANITIDINE HYDROCHLORIDE;RANITIDINE HCL				PC	JAN 14, 2000
>ADD>	020903 001	RIBAVIRIN;REBETOL	5914128	DEC 22, 2017			
	020272 007	RISPERIDONE;RISPERDAL	5158952	DEC 29, 2007	U-90	D-37	OCT 17, 2000
			4804663	DEC 29, 2007	U-90		
	020272 008	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	D-37	OCT 17, 2000
			5158952	DEC 29, 2007	U-90		
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
>ADD>	020980 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-73	NCE	DEC 30, 1999
			4755534	DEC 30, 2006	U-73		
>ADD>	020846 001	TERBINAFINE;LAMISIL				NCE	DEC 30, 1999
>ADD>	019762 001	TESTOSTERONE;TESTODERM	5840327	AUG 15, 2016			
>ADD>	019762 002	TESTOSTERONE;TESTODERM	5840327	AUG 15, 2016			
	020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
			5354760	MAR 24, 2012			
>ADD>	075089 001	TICLOPIDINE HYDROCHLORIDE;TICLOPIDINE HCL				PC	DEC 27, 1999
	020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230		
			5880136	SEP 27, 2010	U-254		
	020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230		
			5880136	SEP 27, 2010	U-254		
	020671 001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN				I-256	NOV 30, 2001
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	019614 004	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007			
	020943 001	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020943 002	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020943 003	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			

*U.S. Government Printing Office: 1999 — 454-723/00013